Intra-Cellular Therapies, Inc.
ITCI · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $199,223 | $175,159 | $161,388 | $144,866 |
| % Growth | 13.7% | 8.5% | 11.4% | – |
| Cost of Goods Sold | $20,405 | $15,304 | $11,354 | $9,900 |
| Gross Profit | $178,818 | $159,855 | $150,034 | $134,966 |
| % Margin | 89.8% | 91.3% | 93% | 93.2% |
| R&D Expenses | $70,286 | $66,819 | $56,183 | $42,833 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $137,729 | $132,101 | $121,574 | $113,085 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$216 | $0 | $0 |
| Operating Expenses | $208,015 | $198,704 | $177,757 | $155,918 |
| Operating Income | -$29,197 | -$38,849 | -$27,723 | -$20,952 |
| % Margin | -14.7% | -22.2% | -17.2% | -14.5% |
| Other Income/Exp. Net | $11,995 | $12,899 | $11,560 | $6,064 |
| Pre-Tax Income | -$17,202 | -$25,950 | -$16,163 | -$14,888 |
| Tax Expense | -$317 | $374 | $57 | $359 |
| Net Income | -$16,885 | -$26,324 | -$16,220 | -$15,247 |
| % Margin | -8.5% | -15% | -10.1% | -10.5% |
| EPS | 0.56 | -0.25 | -0.16 | -0.16 |
| % Growth | 324% | -56.3% | 0% | – |
| EPS Diluted | 0.56 | -0.25 | -0.16 | -0.16 |
| Weighted Avg Shares Out | 103,131 | 105,768 | 103,723 | 96,875 |
| Weighted Avg Shares Out Dil | 103,131 | 105,768 | 103,723 | 96,875 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11,995 | $12,899 | $11,560 | $6,064 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $109 | $138 | $129 | $132 |
| EBITDA | -$29,088 | -$38,711 | -$27,594 | -$20,820 |
| % Margin | -14.6% | -22.1% | -17.1% | -14.4% |